Earnings History Data for Castle Biosciences (CSTL) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Castle Biosciences

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
28-02-2024	AH		CSTL	Castle Biosciences	642.00	-0.10	-0.84	0.00	Castle Biosciences GAAP EPS of -$0.10 beats by $0.46, revenue of $66.12M beats by $4.95M [2/28/2024 4:36 PM]	18.00	-6.39 (-26.20%)	23.99	-0.40 (-1.64%)	9.26 - 26.70	830,890	250,000	85,578
Castle Biosciences GAAP EPS of -$0.10 beats by $0.46, revenue of $66.12M beats by $4.95M [2/28/2024 4:36 PM] Castle Biosciences files for $300M mixed securities shelf [2/28/2024 5:39 PM]
02-11-2023	AH		CSTL	Castle Biosciences, Inc.	418.77	-0.26	-0.92	-0.77	Castle Biosciences GAAP EPS of -$0.26 beats by $0.50, revenue of $61.5M beats by $12.94M [11/2/2023 4:17 PM]	17.99	1.34 (8.05%)	18.21	1.56 (9.37%)	9.26 - 29.59	657,989	350,000	1,909
Castle Biosciences GAAP EPS of -$0.26 beats by $0.50, revenue of $61.5M beats by $12.94M [11/2/2023 4:17 PM]
02-08-2023	AH		CSTL	Castle Biosciences, Inc.	449.75	-0.70	-1.01	-0.06	Castle Biosciences GAAP EPS of -$0.70 beats by $0.22, revenue of $50.1M beats by $5.86M [8/2/2023 4:45 PM]	18.82	2.04 (12.12%)	18.74	1.95 (11.61%)	9.26 - 36.10	685,716	460,000	2,808
Castle Biosciences GAAP EPS of -$0.70 beats by $0.22, revenue of $50.1M beats by $5.86M [8/2/2023 4:45 PM]
03-05-2023	AH	4:05 PM ET (May 3)	CSTL	Castle Biosciences, Inc.	607.12	-1.10	-0.80	-0.80	Castle Biosciences GAAP EPS of -$1.10 misses by $0.21, revenue of $42.04M beats by $4.66M [5/3/2023 5:03 PM]	21.98	-0.93 (-4.04%)	22.91	0.0 (0.00%)	15.58 - 36.10	204,868	80,000	4,416
Castle Biosciences GAAP EPS of -$1.10 misses by $0.21, revenue of $42.04M beats by $4.66M [5/3/2023 5:03 PM]
28-02-2023	AH	4:05 PM ET (Feb 28)	CSTL	Castle Biosciences, Inc.	621.37	-0.78	-0.91	-0.25	Castle Biosciences GAAP EPS of -$0.78 beats by $0.06, revenue of $38.34M in-line, guidance above consensus [2/28/2023 5:00 PM]	22.93	-2.25 (-8.94%)	25.18	0.0 (0.00%)	15.58 - 48.40	403,714	140,000	11,430
Castle Biosciences GAAP EPS of -$0.78 beats by $0.06, revenue of $38.34M in-line, guidance above consensus [2/28/2023 5:00 PM]
02-11-2022	AH	4:05 PM ET (Nov 2)	CSTL	Castle Biosciences, Inc.	671.10	-0.77	-0.70	-0.47	Castle Biosciences Q3 results beat estimates, co raises FY 2022 revenue guidance [11/2/2022 4:47 PM]	24.25	-0.52 (-2.08%)	24.77	0.0 (0.00%)	15.58 - 63.59	234,828	210,000	4,913
Castle Biosciences Q3 results beat estimates, co raises FY 2022 revenue guidance [11/2/2022 4:47 PM] Castle Biosciences to Present at Upcoming Investor Conferences [Nov-01-22 07:00AM] Castle Biosciences Announces Third Quarter 2022 Results [Nov-02-22 04:05PM] Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates [Nov-02-22 06:15PM]
08-08-2022	AH	4:05 PM ET (Aug 8)	CSTL	Castle Biosciences, Inc.	668.08	-0.06	-0.57	-0.34	Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43M [8/8/2022 5:46 PM]	30.58	2.10 (7.37%)	28.48	0.0 (0.00%)	15.58 - 78.58	468,377	210,000	2,297
Castle Biosciences Q2 2022 Earnings Preview [8/8/2022 3:24 AM] Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43M [8/8/2022 5:46 PM] Castle Biosciences stock gains ~9% after co reports beat-and-raise Q2 [8/9/2022 2:30 PM] Castle Biosciences Reports Second Quarter 2022 Results [Aug-08-22 04:05PM]
09-05-2022	AH	4:05 PM ET (May 9)	CSTL	Castle Biosciences, Inc.	557.12	-0.80	-0.67	-0.17	Castle Biosciences GAAP EPS of -$0.97 misses by $0.26, revenue of $26.86M beats by $1.63M [5/9/2022 4:12 PM]	20.23	1.06 (5.53%)	19.17	0.0 (0.00%)	18.51 - 78.92	365,726	400,000	2,077
Castle Biosciences GAAP EPS of -$0.97 misses by $0.26, revenue of $26.86M beats by $1.63M [5/9/2022 4:12 PM] Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety [May-06-22 07:00AM] Castle Biosciences Reports First Quarter 2022 Results [May-09-22 04:05PM] Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates [May-09-22 06:15PM] Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings [May-10-22 07:00AM]
28-02-2022	AH	4:05 PM ET (Feb 28)	CSTL	Castle Biosciences, Inc.	1,100	-0.25	-0.43	-0.16	Castle Biosciences GAAP EPS of -$0.25 beats by $0.23, revenue of $25M beats by $0.85M [2/28/2022 4:15 PM]	46.38	3.09 (7.13%)	43.29	0.0 (0.00%)	31.46 - 84.11	252,245	220,000	1,973
Castle Biosciences GAAP EPS of -$0.25 beats by $0.23, revenue of $25M beats by $0.85M [2/28/2022 4:15 PM] Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results [Feb-28-22 04:05PM] Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates [Feb-28-22 06:15PM] Castle Biosciences to Present at Upcoming Investor Conferences [Mar-01-22 07:00AM]
08-11-2021	AH	4:05 PM ET (Nov 8)	CSTL	Castle Biosciences, Inc.	1,510	-0.47	-0.34	-0.23	Castle Biosciences EPS misses by $0.06, beats on revenue [11/8/2021 4:31 PM]	55.35	-6.16 (-10.01%)	60.19	-1.32 (-2.15%)	43.37 - 107.69	367,107	170,000	207
Castle Biosciences EPS misses by $0.06, beats on revenue [11/8/2021 4:31 PM] Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm [Nov-05-21 05:00PM] Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report [Nov-08-21 07:00AM] Castle Biosciences Announces Third Quarter 2021 Results [Nov-08-21 04:05PM] Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Lags Revenue Estimates [Nov-08-21 05:55PM]
09-08-2021	AH	4:05 PM ET (Aug 9)	CSTL	Castle Biosciences, Inc.	1,750	-0.34	-0.29	-0.08	Castle Biosciences EPS beats by $0.02, beats on revenue [8/9/2021 4:44 PM]	68.43	-3.42 (-4.76%)	71.82	0.0 (0.00%)	38.41 - 107.69	260,679	130,000	2,617
Castle Biosciences EPS beats by $0.02, beats on revenue [8/9/2021 4:44 PM] Castle Biosciences to Present Data at the 2021 American Academy of Dermatology (AAD) Summer Meeting [Aug-06-21 07:00AM] Castle Biosciences Announces Second Quarter 2021 Results [Aug-09-21 04:05PM] Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates [Aug-09-21 06:25PM]
10-05-2021	AH	4:05 PM ET (May 10)	CSTL	Castle Biosciences, Inc.	1,670	-0.17	-0.22	0.03	Castle Biosciences EPS beats by $0.06, beats on revenue [5/10/2021 4:36 PM]	54.42	-0.36 (-0.66%)	60.11	-0.21 (-0.35%)	30.70 - 107.69	419,753	260,000	82
Castle enters pipeline initiative to develop genomic test [5/10/2021 4:10 PM] Castle Biosciences EPS beats by $0.06, beats on revenue [5/10/2021 4:36 PM] Update: Castle Biosciences (NASDAQ:CSTL) Stock Gained 79% In The Last Year [May-07-21 03:37AM] Castle Biosciences Inc to Host Earnings Call [May-10-21 02:30PM] Castle Biosciences Announces First Quarter 2021 Results [May-10-21 04:06PM] Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related Conditions [May-10-21 04:05PM] Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates [May-10-21 05:35PM] Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences Board of Directors [May-11-21 07:00AM]
08-03-2021	AH	4:05 PM ET (Mar 8)	CSTL	Castle Biosciences, Inc.	1,880	-0.16	-0.11	0.11	Castle Biosciences EPS misses by $0.11, beats on revenue [3/8/2021 4:13 PM]	61.48	-4.60 (-6.96%)	62.05	-4.03 (-6.10%)	21.01 - 107.69	758,005	311,944	187
Castle Biosciences EPS misses by $0.11, beats on revenue [3/8/2021 4:13 PM] Castle Biosciences provides update on DecisionDx-Melanoma test [3/8/2021 4:29 PM] Castle Biosciences Sinks 6% On Wider-Than-Expected 4Q Loss, Sales Top Estimates [Mar-09-21 06:14AM] Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates [Mar-08-21 05:35PM] Castle Biosciences: Q4 Earnings Insights [Mar-08-21 04:43PM] Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results [Mar-08-21 04:06PM] Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk [Mar-08-21 04:05PM]
09-11-2020	AH	4:05 PM ET (Nov 9)	CSTL	Castle Biosciences, Inc.	1,030	-0.23	-0.06	-0.31	Castle Biosciences EPS misses by $0.11, beats on revenue [11/9/2020 4:38 PM]	50.00	2.22 (4.65%)	47.90	0.12 (0.25%)	21.01 - 55.31	263,117	145,965	500

10-08-2020	AH	4:05 PM ET (Aug 10)	CSTL	Castle Biosciences, Inc.	818.84	-0.08	-0.41	-1.05	Castle Biosciences EPS beats by $0.32, beats on revenue [8/10/2020 4:17 PM]	40.20	-1.34 (-3.23%)	43.11	1.57 (3.77%)	15.26 - 45.62	252,668	100,390	320